Consider buying Sarepta (SRPT) as a deep-value investment, as its existing drug business is argued to be worth $20-$30 per share, making the stock attractive after its recent collapse. For investors with a very high risk tolerance, Cassava Sciences (SAVA) is flagged as a potential "generational" buying opportunity. A strong bearish view is held against the quantum computing sector, with active short positions in Rigetti (RGTI), D-Wave (QBTS), and IonQ (IONQ). Other conviction trades include a bullish position on ADMA Biologics (ADMA) and a short position in Anavex Life Sciences (AVXL). Finally, the rally in cryptocurrencies like Bitcoin (BTC) is viewed as a sign of excessive market speculation, suggesting investors should be cautious.

Sarepta Therapeutics (SRPT)

• The podcast centers heavily on Sarepta (SRPT), which experienced a significant price drop (down 23% at one point) following news of a patient death in one of its clinical trials.
• Initial Analysis: The speaker initially believed the market was overreacting.
  • The death occurred in a trial for a different drug (SRP 9004 for LGMD), not their main Duchenne Muscular Dystrophy (DMD) drug, Elevitus.
  • He noted that the FDA and the company had known about this death for a month, so it wasn't new information that should have changed the thesis.
  • He personally sold some shares at $28 but expressed that he thought the stock was a buy on the dip.
• The Conference Call: A significant portion of the transcript is a recording of Sarepta's investor call, where the CEO, Doug Ingram, clarified:
  • The decision to discontinue other gene therapy programs was based on financial projections (risk-adjusted NPVs) and the need to focus the pipeline, not the safety event.
  • The safety profile for Elevitus is unchanged. There is a known, rare risk of acute liver failure in more debilitated, non-ambulatory patients.
  • The company had already proactively paused shipments of Elevitus for the non-ambulatory population.
• Major Development: During the podcast, news breaks from Reuters and other outlets (Stat, Bloomberg) that the FDA is preparing to ask Sarepta to halt all shipments of Elevitus, including for the ambulatory (walking) patient population.
  • This is a significant negative turn of events, as the CEO had just reassured investors on the call.
  • The speaker expresses shock and frustration but ultimately decides to buy back into the stock at $13.51.
• Investment Thesis (Post-News): The speaker's rationale for buying after the bad news is based on a deep value and speculative thesis:
  • He believes Sarepta's other approved drugs, the PMO franchise, generate around $900 million in revenue.
  • He argues this existing business alone is worth $20-$30 per share, suggesting the market is pricing it at almost zero. He states that a valuation of 2 times sales for this high-margin business is extremely cheap.
  • The investment becomes a bet on the value of the PMO business, with the potential return of Elevitus acting as a free "call option."
  • He believes there's a chance the halt is temporary (a "pause, not a pull") and the company could get the drug back on the market.

Takeaways

• High-Risk, High-Reward: SRPT is presented as a highly volatile, distressed asset. The investment is a "battleground" stock with significant potential downside but also a potential for a large rebound.
• Know What You Own: The core value proposition shifted mid-podcast. Investors should understand the difference between the Elevitus gene therapy and the PMO drug franchise. The current bull case is built on the value of the PMOs.
• Management Trust: The speaker highlights a complete loss of faith in the current management team, predicting the CEO will be fired. This is a major risk factor.
• Position Sizing is Key: The speaker repeatedly emphasizes the importance of not having an oversized position in such a volatile stock, referencing the Kelly Criterion and suggesting a 10% maximum for most investors.

Quantum Computing Sector

• The speaker is extremely bearish on the entire quantum computing sector.
• He is actively short several quantum computing stocks, including:
  • Rigetti Computing (RGTI)
  • D-Wave Quantum (QBTS)
  • IonQ (IONQ)
• He refers to the sector as "fucking nonsense" and a "fantasy investment," believing there is no real institutional interest.
• The rising prices of these stocks are causing him financial pain ("ripping me a new one") due to margin calls on his short positions, highlighting the risk of shorting momentum-driven stocks.

Takeaways

• Bearish Thesis: The speaker views quantum computing stocks as a speculative bubble with no near-term business fundamentals to support their valuations.
• High Short-Squeeze Risk: While the fundamental view is bearish, the price action shows these stocks are prone to massive rallies. Shorting this sector is extremely risky and can lead to significant losses, as the speaker is experiencing.

Cassava Sciences (SAVA)

• Mentioned briefly but with very high conviction.
• The speaker describes Cassava Sciences (SAVA) as a "true, once in a lifetime, generational opportunity."
• He references it as a past example of a stock where he did immense research to build an 80-90% certainty level before making a huge bet.

Takeaways

• High-Conviction Bull: SAVA is flagged as a major bullish pick for the speaker. For investors interested in high-risk, high-reward biotech, this could be a name to research further, understanding it likely carries significant volatility.

Bitcoin (BTC) & Other Cryptocurrencies

• The speaker notes the recent rallies in XRP and Ethereum (ETH) with skepticism.
• He views the broad crypto rally as a potential sign of a market top or "stretched valuation for the markets in general."
• In a segment using an AI-cloned voice of Warren Buffett, Bitcoin is harshly criticized as a "speculative bubble for degenerates," a "gambling chip," and "digital horseshit" that produces nothing of value.
• Meme coins are dismissed with even more derision as "literal joke currencies."

Takeaways

• Market Indicator: The speaker uses the crypto rally as a contrary indicator, suggesting it's a sign of excessive speculation and froth in the market.
• Caution Advised: The sentiment is overwhelmingly bearish and cautionary. Investors are implicitly warned against chasing these rallies, which are seen as disconnected from fundamental value.

Other Stock & Investment Mentions

• ADMA Biologics (ADMA): The speaker states, "I still like Adma," indicating a bullish stance.
• Anavex Life Sciences (AVXL): Mentioned in a list of shorts: "AVXL is a short." This indicates a bearish stance.
• Uber (UBER): Mentioned favorably: "I like Uber." This indicates a bullish stance.
• BZAI: Described as a "Bizarre company trying to be an AI" with a tiny market cap that has doubled. The tone is skeptical.
• Large-Cap Staples (J&J, P&G, Visa): The AI Buffett voice mentions Johnson & Johnson (JNJ), Procter & Gamble (PG), and Visa (V) as examples of solid companies with strong fundamentals, though the speaker (as himself) notes P&G seems overvalued.